0001178670-22-000013 Sample Contracts

ALNYLAM PHARMACEUTICALS, INC. Performance Stock Unit Award Agreement Granted Under 2018 Stock Incentive Plan

Performance Stock Unit Award Agreement • February 10th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Performance Stock Unit Award Agreement
• Filed
  February 10th, 2022
• Company
  Alnylam Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

Pursuant to the Alnylam Pharmaceuticals, Inc. 2018 Stock Incentive Plan, as amended through the date hereof (the “Plan”), Alnylam Pharmaceuticals, Inc. (the “Company”) hereby grants an award of the number of Performance Stock Units listed above (this “Award”) to the Grantee named above on the Grant Date. Each Performance Stock Unit shall relate to one share of common stock, par value $0.01 per share (the “Stock”) of the Company. Unless earlier terminated, this Award shall have a term of ten (10) years from the Grant Date.

ALNYLAM PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2018 Stock Incentive Plan

Nonstatutory Stock Option Agreement • February 10th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Nonstatutory Stock Option Agreement
• Filed
  February 10th, 2022
• Company
  Alnylam Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

Participant: [ ] ID: [ ] Award Number: [ ] Exercise Price Per Share: [ ] Grant Date: [ ] Vesting Commencement Date: [ ] Expiration Date: [ ] Number of Shares/Units: [ ]

Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENT

Co-Development Agreement • February 10th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Co-Development Agreement
• Filed
  February 10th, 2022
• Company
  Alnylam Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENT (this “Amendment”) is entered into as of November 23, 2021 (the “Effective Date”), by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”), BXLS V Bodyguard – PCP L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware, and BXLS Family Investment Partnership V – ESC L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware (collectively, “Blackstone”) (each, a “Party” and collectively, the “Parties”).